
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="616CF2FE80950DE300F2FE0034D9A1C1.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="lwwopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Acquired Immune Deficiency Syndromes (1999)">
<meta name="citation_title" content="Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia">
<meta name="citation_author" content="Leonardo Calza">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and">
<meta name="citation_author" content="Vincenzo Colangeli">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and">
<meta name="citation_author" content="Maddalena Giglia">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and">
<meta name="citation_author" content="Claudio Rigamonti">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and">
<meta name="citation_author" content="Isabella Bon">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Microbiology, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.">
<meta name="citation_author" content="Silvia Cretella">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and">
<meta name="citation_author" content="Pierluigi Viale">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and">
<meta name="citation_publication_date" content="2025 Jan 14">
<meta name="citation_volume" content="99">
<meta name="citation_issue" content="1">
<meta name="citation_firstpage" content="93">
<meta name="citation_doi" content="10.1097/QAI.0000000000003600">
<meta name="citation_pmid" content="39806529">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/pdf/qai-99-93.pdf">
<meta name="description" content="Dual regimen dolutegravir/lamivudine (DOL/3TC) showed potent efficacy and favorable safety in both antiretroviral therapy-naive and therapy-experienced patients, but data from real life about naive people with high-level viremia are still lacking. ...">
<meta name="og:title" content="Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Dual regimen dolutegravir/lamivudine (DOL/3TC) showed potent efficacy and favorable safety in both antiretroviral therapy-naive and therapy-experienced patients, but data from real life about naive people with high-level viremia are still lacking. ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11970585">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1097/QAI.0000000000003600"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/qai-99-93.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11970585%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11970585/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11970585/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-lwwopen.png" alt="Lippincott Open Access logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Lippincott Open Access" title="Link to Lippincott Open Access" shape="default" href="https://doi.org/10.1097/QAI.0000000000003600" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Acquir Immune Defic Syndr</button></div>. 2025 Jan 14;99(1):93–97. doi: <a href="https://doi.org/10.1097/QAI.0000000000003600" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1097/QAI.0000000000003600</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Acquir%20Immune%20Defic%20Syndr%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Acquir%20Immune%20Defic%20Syndr%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Acquir%20Immune%20Defic%20Syndr%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Acquir%20Immune%20Defic%20Syndr%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Calza%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Leonardo Calza</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Leonardo Calza</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Calza%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Leonardo Calza</span></a>
</div>
</div>
<sup>a,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Colangeli%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Vincenzo Colangeli</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Vincenzo Colangeli</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Colangeli%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vincenzo Colangeli</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Giglia%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Maddalena Giglia</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Maddalena Giglia</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Giglia%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maddalena Giglia</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rigamonti%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Claudio Rigamonti</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Claudio Rigamonti</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rigamonti%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Claudio Rigamonti</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bon%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Isabella Bon</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Isabella Bon</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>b</sup>Department of Medical and Surgical Sciences, Unit of Microbiology, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bon%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Isabella Bon</span></a>
</div>
</div>
<sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cretella%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Silvia Cretella</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Silvia Cretella</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cretella%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Silvia Cretella</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Viale%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Pierluigi Viale</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Pierluigi Viale</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Viale%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pierluigi Viale</span></a>
</div>
</div>
<sup>a</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>a</sup>Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and</div>
<div id="aff2">
<sup>b</sup>Department of Medical and Surgical Sciences, Unit of Microbiology, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</div>
<div class="author-notes p">
<div class="fn" id="corresp1">
<sup>✉</sup><p class="display-inline">Correspondence to: Leonardo Calza, MD, Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via G. Massarenti 11 - I-40138 Bologna, Italy 343500 (e-mail: <span>leonardo.calza@unibo.it</span>).</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Mar 3; Accepted 2024 May 21; Issue date 2025 May 1.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</div>
<p>This is an open access article distributed under the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License 4.0 (CCBY)</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11970585  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39806529/" class="usa-link">39806529</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background:</h3>
<p>Dual regimen dolutegravir/lamivudine (DOL/3TC) showed potent efficacy and favorable safety in both antiretroviral therapy-naive and therapy-experienced patients, but data from real life about naive people with high-level viremia are still lacking.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods:</h3>
<p>We performed a retrospective cohort study of people living with HIV who were naive to antiretroviral therapy, had baseline HIV-1 RNA ranging from 100,000 to 500,000 copies/mL, and initiated DOL/3TC. Virologic efficacy and changes in immunologic parameters after 12 months of treatment were evaluated and compared with highly viremic people living with HIV who started a triple antiretroviral combination.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results:</h3>
<p>Inclusion criteria were met by 58 patients with median age of 43.4 years. At baseline, mean HIV RNA was 5.4 log<sub>10</sub> and mean CD4 T lymphocyte count was 488 cells/mm<sup>3</sup>. HIV RNA &lt;50 copies/mL was obtained in 45 patients (77.6% in the intention-to-treat analysis) after 6 months and in 53 patients (91.4%) after 12 months. Reasons for treatment failure were virologic failure in 2 cases and adverse events in 3 cases. No significant changes in median value of lipids were reported, while there was a not significant increase in body weight (+1.18 kg). Virologic and immunologic response at month 12 in patients on DOL/3TC was comparable with that observed in 50 naive patients with high-level viremia and starting a triple antiretroviral therapy.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions:</h3>
<p>In this real-life cohort of naive patients with high-level viremia, DOL/3TC was associated with high virologic efficacy and good tolerability after 12 months, supporting use of this dual regimen also in persons with high initial viremia.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Key Words:</strong> dual therapy, viremia, resistance, efficacy, tolerability</p></section></section><section id="s1"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Combination antiretroviral therapy (cART) recommended in treatment-naive people living with HIV-1 (PLWH) usually comprises 3 active antiretroviral agents from 2 drug classes, and allows them to achieve and maintain long-term virologic suppression in association with a life expectancy comparable with that of the general population. Despite their efficacy, many antiretroviral agents are associated with potential long-term toxicities, including metabolic disorders, cardiovascular disease, osteoporosis, and renal dysfunction, and the increasing prevalence of comorbidities in aging PLWH leads to polypharmacy and a higher risk of drug–drug interactions.<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a>–<a href="#R5" class="usa-link" aria-describedby="R5">5</a></sup></p>
<p>Two-drug regimens (2DR) reduce the number of antiretroviral drugs PLWH are exposed and may decrease the risk of long-term toxicities, drug–drug interactions, and costs. The optimal antiretroviral agents in a 2DR should have potent and persistent antiviral activity, high genetic barrier, and good tolerability.</p>
<p>The integrase strand transfer inhibitor (INSTI) dolutegravir is characterized by a potent antiviral activity and a high genetic barrier, and is an optimal candidate for a 2DR in association with the well-tolerated nucleoside reverse transcriptase inhibitor lamivudine. In randomized trials and observational studies, the 2DR dolutegravir/lamivudine (DOL/3TC) has shown noninferior efficacy in comparison with traditional 3-drug regimens (3DR) in both antiretroviral therapy-naive and therapy-experienced PLWH.<sup><a href="#R6" class="usa-link" aria-describedby="R6">6</a>–<a href="#R10" class="usa-link" aria-describedby="R10">10</a></sup></p>
<p>In GEMINI-1 and GEMINI-2 multicenter, double-blind, randomized trials, the 2DR dolutegravir plus lamivudine was noninferior to 3DR dolutegravir plus tenofovir disoproxil fumarate/emtricitabine after 3 years, showing high barrier to viral resistance and long-term tolerability.<sup><a href="#R6" class="usa-link" aria-describedby="R6">6</a></sup> In a systematic review and meta-analysis including 14 randomized controlled trials evaluating the efficacy and/or safety of dolutegravir plus lamivudine in comparison with guideline-recommended 3DR in 10,043 naive PLWH, efficacy and safety outcomes for 48 weeks were similar for 2DR and 3DR.<sup><a href="#R7" class="usa-link" aria-describedby="R7">7</a></sup></p>
<p>In randomized trials, proportion of participants with HIV RNA &lt;50 copies/mL obtained with dolutegravir plus lamivudine was comparable with that of 3DR also in patients with baseline HIV RNA ranging from 100,000 to 500,000 copies/mL,<sup><a href="#R6" class="usa-link" aria-describedby="R6">6</a>,<a href="#R7" class="usa-link" aria-describedby="R7">7</a></sup> but data about virologic efficacy in subjects with high-level viremia at baseline are still lacking in clinical practice.</p>
<p>The aim of our observational study is to evaluate efficacy and safety of 2DR dolutegravir/lamivudine in antiretroviral therapy-naive PLWH with initial high-level HIV viral load.</p></section><section id="s2"><h2 class="pmc_sec_title">METHODS</h2>
<p>We performed a single-center, observational, retrospective study of adult PLWH naive to antiretroviral therapy, referred to our Clinic of Infectious Diseases from January, 2020, through December, 2022, with baseline plasma HIV RNA ranging from 100,000 to 500,000 copies/mL, with baseline genotypic testing, and who initiated the daily single-tablet regimen DOL/3TC or a daily single-tablet 3DR. Candidates were those who received at least 1 dose of antiretroviral treatment. All enrolled subjects were followed for 12 months.</p>
<p>Exclusion criteria were having received a previous antiretroviral treatment for &gt;7 days, baseline genotypic testing showing reduced sensitivity to lamivudine or dolutegravir or other drugs included in the antiretroviral combination, chronic hepatitis B virus infection, pregnancy, alcohol abuse or intravenous drug use, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;80 U/L, creatinine &gt;1.5 mg/dL, and treatment with medications or herbal supplements known to affect the pharmacokinetics of current antiretroviral drugs. Alcohol abuse and intravenous drug dependence were defined as a daily alcohol consumption &gt;30 g and ≥1 intravenous drug use within 6 months before starting the dual regimen, respectively.</p>
<p>Demographic, clinical, and laboratory data were recorded at the start of therapy and at 6-month intervals during the 12-month follow-up. All the available data were collected during routine clinical care. All the plasma samples were analyzed for HIV-RNA level using the automated COBAS AmpliPrep Instrument for specimen processing and the COBAS TaqMan Analyzer for amplification and detection (Roche CobasAmpliPrep/Cobas TaqMan HIV-1 tests version 2.0; Roche Diagnostics, Mannheim, Germany).</p>
<p>In the DOL/3TC group, the primary end point was the virologic success at month 12. Results were evaluated both in intention-to-treat (ITT) and per-protocol (PP) analyses. The ITT analyses included all subjects with at least 1 dose of drug taken and participants who were lost to follow-up, discontinued or changed antiretroviral therapy, died, or had no data at month 12 were considered failures. The PP analysis included all the ITT patients except those with loss of follow-up, who had no 12-month data, or discontinued or changed antiretroviral regimen for reasons other than a virologic failure. The secondary end points included changes in CD4<sup>+</sup> lymphocyte count, CD4+/CD8+ lymphocyte ratio, metabolic parameters, weight, and body mass index at month 12. Significant weight increase was defined as an increase ≥5% of the baseline weight at month 12.</p>
<p>Virologic success was defined as plasma HIV RNA &lt;50 copies/mL at month 12, and virologic failure as a confirmed plasma HIV RNA ≥50 copies/mL at month 12. Genotypic testing was performed in case of virologic failure. Regarding safety evaluations, the occurrence of adverse events and treatment discontinuation for adverse events were reported by the clinicians in medical records and gathered from their review.</p>
<p>In the 3DR group, only virologic and immunologic responses were evaluated at 12 months and compared with virologic and immunologic efficacy reported in the DOL/3TC group.</p>
<p>The adherence to the current therapy was carefully checked every 6 months on the outpatient visits by self-reported questionnaires. The adopted questionnaire asked how many pills the patients forgot in the past month, in the past week, and in the past 3 days, and led to an evaluation of the treatment adherence as very satisfying (&gt;95%), satisfying (between 85% and 95%), or unsatisfying (&lt;85%). The study was approved by the ethic committee of the S. Orsola-Malpighi Hospital and all participants signed an informed consent after receiving information about the purpose of the study.</p>
<section id="s2-1"><h3 class="pmc_sec_title">Statistical Analysis</h3>
<p>Data are presented as median with interquartile range (IQR) for descriptive data, while comparisons between groups were performed by Student <em>t</em> test or Fisher exact test (where appropriate). The significance of changes in all the considered variables was assessed using the paired Student <em>t</em> test. Depending on the distribution, the <em>t</em> test or Wilcoxon rank-sum test was used to analyze continuous data. All statistical tests were bilateral and a <em>P</em> value of &lt;0.05 was considered statistically significant. Excel 2007–2013 (Microsoft, Redmond, WA) was used to input the data, and SPSS 23.0 (IBM, Armonk, NY) was used for statistical analysis.</p></section></section><section id="s3"><h2 class="pmc_sec_title">RESULTS</h2>
<p>Study inclusion criteria were met by 58 patients starting DOL/3TC and 50 starting a 3DR, who were enrolled in the study. In the DOL/3TC group, median age (IQR) was 43.4 (24, 58) years, 49 patients (84.5%) were men, and 55 patients (94.8%) were White. The median baseline log<sub>10</sub> HIV RNA (IQR) was 5.4 (5.1, 5.6), and 21 patients (36.2%) had HIV RNA ranging from 250,000 to 500,000 copies/mL. Median baseline CD4<sup>+</sup> lymphocyte count was 488 cells/mm<sup>3</sup>, 21 subjects (36.2%) had a CD4<sup>+</sup> lymphocyte count &lt;350 cells/mm<sup>3</sup>, and 5 (8.6%) subjects had AIDS diagnosis.</p>
<p>At baseline, 10 patients (17.2%%) had 1 or more comorbidities, and the most common comorbidities were hypertension (10.3% of patients), neuropsychiatric disorders (6.9%), and osteoporosis (6.9%). Notably, we found that the median time from HIV-1 infection confirmation to cART initiation was 6.4 days, and it was less than 10 days in all patients.</p>
<p>Baseline characteristics of patients in the DOL/3TC group were comparable with those of patients in the 3DR group and are summarized in Table <a href="#T1" class="usa-link">1</a>. In the 3DR group, triple antiretroviral regimen included bictegravir/emtricitabine/tenofovir alafenamide in 26 patients (52%), doravirine/lamivudine/tenofovir disoproxil fumarate in 20 patients (40%), and darunavir/cobicistat/emtricitabine/tenofovir alafenamide in 4 patients (8%).</p>
<section class="tw xbox font-sm" id="T1"><h3 class="obj_head">TABLE 1.</h3>
<div class="caption p"><p>Baseline Characteristics of the Enrolled Patients</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<td rowspan="1" colspan="1">ARV Therapy</td>
<td rowspan="1" colspan="1">DOL/3TC</td>
<td rowspan="1" colspan="1">3DR</td>
<td rowspan="1" colspan="1">
<em>P</em>
</td>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">No. of patients</td>
<td rowspan="1" colspan="1">58</td>
<td rowspan="1" colspan="1">50</td>
<td align="center" rowspan="1" colspan="1">0.761</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Males, no. (%)</td>
<td rowspan="1" colspan="1">49 (84.5)</td>
<td rowspan="1" colspan="1">42 (84)</td>
<td align="center" rowspan="1" colspan="1">0.309</td>
</tr>
<tr>
<td rowspan="1" colspan="1">White subjects, no. (%)</td>
<td rowspan="1" colspan="1">55 (94.8)</td>
<td rowspan="1" colspan="1">46 (92)</td>
<td align="center" rowspan="1" colspan="1">0.288</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Age (yr), median (IQR)</td>
<td rowspan="1" colspan="1">43.4 (24, 58)</td>
<td rowspan="1" colspan="1">45.2 (27, 63)</td>
<td align="center" rowspan="1" colspan="1">0.178</td>
</tr>
<tr>
<td rowspan="1" colspan="1">HIV transmission risk category, no. (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> IDU</td>
<td rowspan="1" colspan="1">2 (3)</td>
<td rowspan="1" colspan="1">4 (8)</td>
<td align="center" rowspan="1" colspan="1">0.912</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> MSM</td>
<td rowspan="1" colspan="1">37 (64)</td>
<td rowspan="1" colspan="1">27 (54)</td>
<td align="center" rowspan="1" colspan="1">0.461</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Heterosexual</td>
<td rowspan="1" colspan="1">19 (33)</td>
<td rowspan="1" colspan="1">19 (38)</td>
<td align="center" rowspan="1" colspan="1">0.507</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Log<sub>10</sub> HIV RNA (copies/mL), median (IQR)</td>
<td rowspan="1" colspan="1">5.4 (5.1, 5.6)</td>
<td rowspan="1" colspan="1">5.5 (5.1, 5.7)</td>
<td align="center" rowspan="1" colspan="1">0.881</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CD4<sup>+</sup> lymphocyte count (cells/mm<sup>3</sup>), median (IQR)</td>
<td rowspan="1" colspan="1">488 (95, 886)</td>
<td rowspan="1" colspan="1">402 (65, 774)</td>
<td align="center" rowspan="1" colspan="1">0.209</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CD4<sup>+</sup>/CD8<sup>+</sup> lymphocyte ratio, median (IQR)</td>
<td rowspan="1" colspan="1">0.54 (0.22, 0.78)</td>
<td rowspan="1" colspan="1">0.56 (0.19, 0.87)</td>
<td align="center" rowspan="1" colspan="1">0.176</td>
</tr>
<tr>
<td rowspan="1" colspan="1">AIDS diagnosis, no. (%)</td>
<td rowspan="1" colspan="1">5 (8.6)</td>
<td rowspan="1" colspan="1">6 (12)</td>
<td align="center" rowspan="1" colspan="1">0.829</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Patients with CD4<sup>+</sup> lymphocyte count &lt;350 cells/mm<sup>3</sup>, no (%)</td>
<td rowspan="1" colspan="1">21 (36.2)</td>
<td rowspan="1" colspan="1">23 (46)</td>
<td align="center" rowspan="1" colspan="1">0.105</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Patients with CD4<sup>+</sup> lymphocyte count &lt;200 cells/mm<sup>3</sup>, no (%)</td>
<td rowspan="1" colspan="1">8 (13.8)</td>
<td rowspan="1" colspan="1">6 (12)</td>
<td align="center" rowspan="1" colspan="1">0.371</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Patients with ≥1 comorbidities, no (%)</td>
<td rowspan="1" colspan="1">10 (17.2)</td>
<td rowspan="1" colspan="1">11 (22)</td>
<td align="center" rowspan="1" colspan="1">0.345</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Patients with hypertension, no (%)</td>
<td rowspan="1" colspan="1">6 (10.3)</td>
<td rowspan="1" colspan="1">7 (14)</td>
<td align="center" rowspan="1" colspan="1">0.682</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Weight (kg), median (IQR)</td>
<td rowspan="1" colspan="1">72.4 (61.3, 85.2)</td>
<td rowspan="1" colspan="1">74.1 (58.8, 90.2)</td>
<td align="center" rowspan="1" colspan="1">0.438</td>
</tr>
<tr>
<td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (IQR)</td>
<td rowspan="1" colspan="1">23.6 (21.5, 26.3)</td>
<td rowspan="1" colspan="1">23.9 (22.1, 26.8)</td>
<td align="center" rowspan="1" colspan="1">0.517</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Total cholesterol (mg/dL), median (IQR)</td>
<td rowspan="1" colspan="1">204 (179, 247)</td>
<td rowspan="1" colspan="1">211 (154, 266)</td>
<td align="center" rowspan="1" colspan="1">0.198</td>
</tr>
<tr>
<td rowspan="1" colspan="1">LDL cholesterol (mg/dL), median (IQR)</td>
<td rowspan="1" colspan="1">139 (102, 168)</td>
<td rowspan="1" colspan="1">142 (94, 181)</td>
<td align="center" rowspan="1" colspan="1">0.246</td>
</tr>
<tr>
<td rowspan="1" colspan="1">HDL cholesterol (mg/dL), median (IQR)</td>
<td rowspan="1" colspan="1">49 (34, 71)</td>
<td rowspan="1" colspan="1">45 (31, 68)</td>
<td align="center" rowspan="1" colspan="1">0.313</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Triglycerides (mg/dL), median (IQR)</td>
<td rowspan="1" colspan="1">216 (144, 287)</td>
<td rowspan="1" colspan="1">210 (135, 306)</td>
<td align="center" rowspan="1" colspan="1">0.219</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Creatinine (mg/dL), median (IQR)</td>
<td rowspan="1" colspan="1">0.91 (0.79, 1.16)</td>
<td rowspan="1" colspan="1">0.82 (0.72, 1.02)</td>
<td align="center" rowspan="1" colspan="1">0.527</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn1"><p>BMI, body mass index; HDL, high-density lipoprotein cholesterol; IDU, injection drug users; LDL cholesterol, low-density lipoprotein cholesterol; MSM, men who have sex with men.</p></div></div></section><p>In the DOL/3TC group, after 6 months of treatment, the proportion of patients with virologic success was 77.6% (45/58) by the ITT analysis and 78.9% (45/57) by the PP analysis. After 12 months, the proportion of patients with virologic success was 91.4% (53/58) by the ITT analysis and 96.4% (53/55) by the PP analysis.</p>
<p>After 12 months, 5 treatment failures (8.6%) were observed: 2 discontinuations (3.4%) due to virologic failure and 3 discontinuations (5.2%) due to nonserious adverse events (Table <a href="#T2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="T2"><h3 class="obj_head">TABLE 2.</h3>
<div class="caption p"><p>Virologic and Immunologic Results at Month 12</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<td rowspan="1" colspan="1">ARV Therapy</td>
<td rowspan="1" colspan="1">DOL/3TC</td>
<td rowspan="1" colspan="1">3DR</td>
<td rowspan="1" colspan="1">
<em>P</em>
</td>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">No. of enrolled patients</td>
<td rowspan="1" colspan="1">58</td>
<td rowspan="1" colspan="1">50</td>
<td align="center" rowspan="1" colspan="1">0.761</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Treatment failures, no. (%)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Discontinuations due to AE</td>
<td rowspan="1" colspan="1">3 (5.2)</td>
<td rowspan="1" colspan="1">2 (4)</td>
<td align="center" rowspan="1" colspan="1">0.882</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Virologic failures</td>
<td rowspan="1" colspan="1">2 (3.4)</td>
<td rowspan="1" colspan="1">2 (4)</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Missing data</td>
<td rowspan="1" colspan="1">0</td>
<td rowspan="1" colspan="1">0</td>
<td align="center" rowspan="1" colspan="1">0.491</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Virologic successes (patients with HIV RNA&lt;50 copies/mL)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> ITT analysis, (%)</td>
<td rowspan="1" colspan="1">53/58 (91.4)</td>
<td rowspan="1" colspan="1">46/50 (92)</td>
<td align="center" rowspan="1" colspan="1">0.301</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> PP Analysis (%)</td>
<td rowspan="1" colspan="1">53/55 (96.4)</td>
<td rowspan="1" colspan="1">46/48 (95.8)</td>
<td align="center" rowspan="1" colspan="1">0.517</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Median change from baseline to month 12 in CD4<sup>+</sup> lymphocyte count (cells/mm<sup>3</sup>), (IQR)</td>
<td rowspan="1" colspan="1">+145 (+58, +271)</td>
<td rowspan="1" colspan="1">+167 (+62, +302)</td>
<td align="center" rowspan="1" colspan="1">0.228</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Median change from baseline to month 12 in CD4<sup>+</sup>/CD8<sup>+</sup> lymphocyte ratio, (IQR)</td>
<td rowspan="1" colspan="1">+0.18 (+0.09, +0.37)</td>
<td rowspan="1" colspan="1">+0.21 (+0.08, +0.42)</td>
<td align="center" rowspan="1" colspan="1">0.313</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p>AE, adverse events; IQR, interquartile range; ITT, intention-to-treat; PP, per-protocol.</p></div></div></section><p>In the first case of virologic failure, HIV RNA was 660 copies/mL at month 12, and genotypic analysis demonstrated no resistance mutations. This patient restarted antiretroviral therapy with tenofovir alafenamide/emtricitabine/bictegravir and reached a plasma HIV RNA &lt;50 copies/mL within 3 months.</p>
<p>In the second case of virologic failure, HIV RNA was 490 copies/mL at month 12, and genotypic analysis demonstrated no resistance mutations. This patient restarted antiretroviral therapy with tenofovir alafenamide/emtricitabine plus dolutegravir and reached a plasma HIV RNA &lt;50 copies/mL within 3 months.</p>
<p>Patient's adherence to antiretroviral treatment was unsatisfying in both cases of virologic failure. Overall, adherence to medications was very satisfying in 50 out of 58 (86.2%) patients.</p>
<p>There were 3 discontinuations for nonserious adverse events (5.2%): insomnia with sleep disturbances in 1 case (1.7%), headache in 1 case (1.7%), and abdominal pain in 1 case (1.7%).</p>
<p>After 12 months, the median increase (IQR) in CD4<sup>+</sup> lymphocyte count was +145 cells/mm<sup>3</sup> (+58, +271) and the number of patients with CD4<sup>+</sup> lymphocyte count ≥350 cells/mm<sup>3</sup> increased from 37 (63.8%) to 51 (87.9%). The median increase (IQR) from baseline to month 12 in CD4+/CD8+ lymphocyte ratio was +0.18 (+0.09, +0.37) (Table <a href="#T2" class="usa-link">2</a>).</p>
<p>In the 3DR group, virologic and immunologic responses at month 12 were comparable with those reported in the DOL/3TC group. The proportion of patients with virologic success was 92% (46/50) by the ITT analysis and 95.8% (46/48) by the PP analysis. Four treatment failures (8%) were observed: 2 discontinuations (4%) due to virologic failure and 2 discontinuations (4%) due to nonserious adverse events. After 12 months, the median increase (IQR) in CD4<sup>+</sup> lymphocyte count was +167 cells/mm<sup>3</sup> (+62, +302) and the median increase (IQR) in CD4+/CD8+ lymphocyte ratio was +0.21 (+0.08, +0.42) (<em>P</em> = 0.39) (Table <a href="#T2" class="usa-link">2</a>).</p>
<p>In the DOL/3TC group, during the 12-month follow-up, no significant changes in median concentrations (IQR) of total cholesterol (+16 mg/dL; −7, +28, <em>P</em> = 0.711), HDL cholesterol (+0.05 mg/dL; −0.02, +0.08, <em>P</em> = 0.817), LDL cholesterol (+8 mg/dL; −4, +15, <em>P</em> = 0.605), and triglycerides (+44 mg/dL; −4, +73, <em>P</em> = 0.189) were observed.</p>
<p>In terms of kidney and liver function tests, the results demonstrated that changes in median level of both creatinine (+0.15 mg/dL; −0.02, +0.28, <em>P</em> = 0.061) and alanine aminotransferase (−3 U/L; −8, + 2, <em>P</em> = 0.548) were not significant. At the same time, a slight and not significant increase in median value (IQR) of weight (+1.18 kg; −0.17, + 1.92, <em>P</em> = 0.314) and body mass index (+0.28 kg/m<sup>2</sup>; −0.09, + 0.34, <em>P</em> = 0.097) was reported at month 12, and no patients had an increase ≥5% in comparison with the baseline weight.</p>
<p>No serious adverse events were reported during the 12-month follow-up, and no grade 3 or 4 clinical events or laboratory abnormalities were recorded in both DOL/3TC and 3DR groups. In the DOL/3TC group, adverse events were described in 11 individuals (18.9%). The most common adverse events were sleeping disturbances (5 patients; 8.6%), diarrhea with abdominal discomfort (3; 5.2%), and headache (3; 5.2%). All reported adverse events were grade 1 or 2.</p></section><section id="s4"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p>The antiviral potency of an antiretroviral regimen is carefully predicted by its virologic efficacy in subjects with high-level viremia. In large cohorts of naive PLWH, baseline HIV viral load &gt;100,000 copies/mL is associated with lower rate of virologic suppression and higher risk of viral blips after 1 or 2 years of initial cART.<sup><a href="#R11" class="usa-link" aria-describedby="R11">11</a>,<a href="#R12" class="usa-link" aria-describedby="R12">12</a></sup> Moreover, the dual regimen ritonavir-boosted darunavir plus raltegravir failed to demonstrate a noninferior efficacy compared with a standard 3DR in individuals with baseline HIV RNA &gt;100,000 copies/mL,<sup><a href="#R13" class="usa-link" aria-describedby="R13">13</a></sup> so it is crucial to evaluate the potency of a 2DR in naive patients with high initial viremia.</p>
<p>In our study, initial cART with single-tablet <a href="#T2" class="usa-link">2</a>DR DOL/3TC was effective in a cohort of 58 PLWH with baseline high-level viremia (HIV RNA ≥100,000 and &lt;500,000 copies/mL), with high rates of virologic suppression (91.4% in the ITT analysis) and a significant increase in median CD4 lymphocyte count (+145 cells/mm<sup>3</sup>) after a 12-month follow-up. Only 2 patients had confirmed virologic failure, but genotype testing showed no resistance-associated mutations for INSTIs or NRTIs.</p>
<p>Moreover, virologic and immunologic efficacy at month 12 was comparable in subjects treated with DOL/3TC and in those with similar baseline viral load and treated with a 3DR.</p>
<p>DOL/3TC showed a favorable safety profile for 12 months of treatment: no serious or grade 3–4 adverse events were reported, and only 3 subjects discontinued treatment because of nonserious adverse events (sleep disturbances, headache, and abdominal pain), while mild neuropsychiatric adverse effects were reported in 8 cases (13.8%).</p>
<p>Starting DOL/3TC did not lead to significant changes in lipid parameters or hepatic and renal function tests, and a small and no significant increase in median body weight was described (+1.18 kg).</p>
<p>To investigate antiviral potency of the 2DR dolutegravir plus lamivudine versus the standard 3DR dolutegravir plus tenofovir disoproxil fumarate/emtricitabine, a post hoc analysis was performed assessing antiviral response rates in the GEMINI-1 and GEMINI-2 randomized trials. In 293 participants with baseline viral load &gt;100,000 copies/mL, median change in viral load from baseline at week 4 was −3.38 and −3.4 log<sub>10</sub> copies/mL in the 2DR and 3DR groups, respectively. The median reduction in viral load was comparable between groups and was maintained through 48 weeks. At week 24, the proportion of patients with HIV RNA &lt;50 copies/mL was similarly high in both groups, and similar rates of viral suppression were observed in the Snapshot analysis at week 48 in the 2DR and 3DR groups of patients with baseline viremia &gt;100,000 copies/mL (92% and 90%, respectively). No patients with confirmed virologic failure had treatment-emergent INSTI- or NRTI-associated resistance mutations.<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a></sup></p>
<p>A retrospective–prospective observational study enrolled 42 naive PLWH who started DOL/3TC and compared virologic response between 20 subjects with baseline low viral load (&lt;500,000 copies/mL) and 22 with baseline high viral load (≥500,000 copies/mL). At week 48, there was no significant difference in proportions of patients with HIV RNA &lt;50 copies/mL between groups (90% in the low viral load group and 95.5% in the high viral load group), such as changes in CD4<sup>+</sup> lymphocyte count were similar in both groups.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup></p>
<p>In the DOLAVI observational, prospective, single-arm study, 88 naive PLWH starting cART with dolutegravir plus lamivudine were enrolled, and 17 had baseline HIV RNA &gt;100,000 copies/mL. At week 48, the follow-up was completed by 14 subjects with high initial viremia and all of them had HIV RNA &lt;50 copies/mL.<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a></sup> A prospective, cohort study compared 140 naive patients who received initial cART of either 2DR dolutegravir plus lamivudine or 3DR efavirenz plus tenofovir disoproxil fumarate plus lamivudine. The study included 26 subjects with baseline viral load &gt;500,000 copies/mL, and at week 48, all patients with high initial viremia had HIV RNA &lt;50 copies/mL in both the 2DR and 3DR groups.<sup><a href="#R17" class="usa-link" aria-describedby="R17">17</a></sup> A retrospective multicenter study of PLWH starting DOL/3TC as a first-line regimen included 135 participants, 23 of whom (17%) had baseline HIV RNA &gt;100,000 copies/mL. The proportion of participants with viral suppression at week 48 was 85.2% in the ITT analysis, and all patients with high basal viremia were suppressed and continued treatment with DOL/3TC except 2 who were lost to follow-up.<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup> In a retrospective cohort analysis of 276 naive PLWH who initiated 2DR dolutegravir plus lamivudine or 3DR tenofovir alafenamide/emtricitabine/bictegravir, at week 48 the proportion of patients with virologic suppression was comparable in both groups, and there was no significant difference between groups in virologic efficacy also for 44 subjects with basal viremia &gt;100,000 copies/mL.<sup><a href="#R19" class="usa-link" aria-describedby="R19">19</a></sup> In all these studies, no resistance-associated mutations emerged in patients with virologic failure.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a>–<a href="#R19" class="usa-link" aria-describedby="R19">19</a></sup></p>
<p>The 2DR DOL/3TC has been evaluated also as a first-line regimen in a test-and-treat setting for newly diagnosed PLWH. In the STAT multicenter, single-arm, pilot study, 133 subjects initiated DOL/3TC 14 days or less after HIV-1 diagnosis, and 39% of participants had a baseline HIV RNA &gt;100,000 copies/mL. At week 24, 82% of all subjects in the ITT analysis achieved HIV RNA &lt;50 copies/mL, and virologic suppression was obtained in the same percentage of patients with initial viremia &gt;100,000 copies/mL.<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup></p>
<p>It is unknown whether the treatment initiation with a 2DR has a different impact on the immunologic parameters and the CD4/CD8 ratio recovery compared with a 3DR. Using observational data from the Spanish HIV Research Network cohort (CoRIS), 3318 individuals who started 2DR dolutegravir plus lamivudine or a dolutegravir- or bictegravir-based 3DR were evaluated, including 1100 subjects (33.1%) with baseline high-level viremia (≥100,000 copies/mL). At week 48, there were no differences between 2DR and 3DR in the rate of CD4/CD8 ratio normalization, and the CD4/CD8 ratio increase was similar in patients with initial low-level or high-level viremia.<sup><a href="#R21" class="usa-link" aria-describedby="R21">21</a></sup></p>
<p>Our work clearly presents several limitations. First, it was a monocentric, observational, retrospective study with a limited sample size. Second, in our study high-level viremia was defined as a HIV RNA ranging from 100,000 to 500,000 copies/mL, because DOL/3TC is contraindicated by the European AIDS Clinical Society Guidelines<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup> in naive patients with HIV RNA &gt;500,000 copies/mL. However, clinical data about efficacy of DOL/3TC as initial regimen with baseline HIV RNA &gt;500,000 copies/mL are lacking, but they should be necessary to define more precisely the efficacy of this 2DR in naive individuals with initial very high viremia. Third, some aspects, such as the control of viral replication in the central nervous system or other reservoirs and the effect on the immune activation markers or peripheral fat, were not evaluated in this study.</p>
<p>To conclude, in clinical practice, the dual combination dolutegravir/lamivudine in a single-tablet regimen represents an effective and safe initial regimen in antiretroviral therapy-naive PLWH with baseline high-level viremia (between 100,000 and 500,000 copies/mL), but larger randomized and observational studies are needed to better evaluate the efficacy of this dual therapy in individuals with initial high and very high HIV viral load.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn3"><p>L.C. has received research grant and speaker honorarium from companies Gilead, ViiV, and MERCK. P.Viale received research grant and speaker honorarium from companies Gilead, ViiV, MERCK, and Janssen, and attended advisory boards of Gilead, ViiV, MERCK, and Janssen.</p></div>
<div class="fn p" id="fn4"><p>The authors have no funding or conflicts of interest to disclose.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Vincenzo Colangeli, Email: vincenzo.colangeli@aosp.bo.it.</p>
<p>Maddalena Giglia, Email: maddalena.giglia@studio.unibo.it.</p>
<p>Claudio Rigamonti, Email: claudio.rigamonti@studio.unibo.it.</p>
<p>Isabella Bon, Email: isabella.bon@unibo.it.</p>
<p>Silvia Cretella, Email: silvia.cretella1605@gmail.com.</p>
<p>Pierluigi Viale, Email: Pierluigi.Viale@Unibo.It.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (Updated December 2023). Available at: <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</a>. Accessed February 20, 2024.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Guidelines%20for%20the%20Use%20of%20Antiretroviral%20Agents%20in%20Adults%20and%20Adolescents%20Living%20with%20HIV%20(Updated%20December%202023)&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>EACS European AIDS Clinical Society. Guidelines. Version 12.0. (Updated October 2023). Available at: <a href="https://www.eacsociety.org/media/guidelines-12.0.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.eacsociety.org/media/guidelines-12.0.pdf</a>. Accessed February 20, 2024.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Guidelines.%20Version%2012.0.%20(Updated%20October%202023)&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27:973–979.
</cite> [<a href="https://doi.org/10.1097/QAD.0b013e32835cae9c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23698063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Mortality%20in%20well%20controlled%20HIV%20in%20the%20continuous%20antiretroviral%20therapy%20arms%20of%20the%20SMART%20and%20ESPRIT%20trials%20compared%20with%20the%20general%20population&amp;author=AJ%20Rodger&amp;author=R%20Lodwick&amp;author=M%20Schechter&amp;volume=27&amp;publication_year=2013&amp;pages=973-979&amp;pmid=23698063&amp;doi=10.1097/QAD.0b013e32835cae9c&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30:613–628.
</cite> [<a href="https://doi.org/10.1007/s40266-013-0093-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3715685/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23740523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs%20Aging&amp;title=The%20next%20therapeutic%20challenge%20in%20HIV:%20polypharmacy&amp;author=EJ%20Edelman&amp;author=KS%20Gordon&amp;author=J%20Glover&amp;volume=30&amp;publication_year=2013&amp;pages=613-628&amp;pmid=23740523&amp;doi=10.1007/s40266-013-0093-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47:1429–1439.
</cite> [<a href="https://doi.org/10.1177/1060028013504075" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24285760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Pharmacother&amp;title=Association%20of%20age%20with%20polypharmacy%20and%20risk%20of%20drug%20interactions%20with%20antiretroviral%20medications%20in%20HIV-positive%20patients&amp;author=A%20Tseng&amp;author=L%20Szadkowski&amp;author=S%20Walmsley&amp;volume=47&amp;publication_year=2013&amp;pages=1429-1439&amp;pmid=24285760&amp;doi=10.1177/1060028013504075&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection. AIDS. 2022;36:39–48.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000003070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8654248/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34534138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Three-year%20durable%20efficacy%20of%20dolutegravir%20plus%20lamivudine%20in%20antiretroviral%20therapy-naive%20adults%20with%20HIV-1%20infection&amp;author=P%20Cahn&amp;author=J%20Sierra%20Madero&amp;author=JR%20Arribas&amp;volume=36&amp;publication_year=2022&amp;pages=39-48&amp;pmid=34534138&amp;doi=10.1097/QAD.0000000000003070&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Radford M, Parks DC, Ferrante S, et al. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS. 2019;33:1739–1749.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000002285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6686958/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31180906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Comparative%20efficacy%20and%20safety%20and%20dolutegravir%20and%20lamivudine%20in%20treatment%20naive%20HIV%20patients&amp;author=M%20Radford&amp;author=DC%20Parks&amp;author=S%20Ferrante&amp;volume=33&amp;publication_year=2019&amp;pages=1739-1749&amp;pmid=31180906&amp;doi=10.1097/QAD.0000000000002285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75:975–986.
</cite> [<a href="https://doi.org/10.1093/cid/ciac036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9639798/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35079789/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Efficacy%20and%20safety%20of%20switching%20to%20dolutegravir/lamivudine%20versus%20continuing%20a%20tenofovir%20alafenamide-based%203-%20or%204-drug%20regimen%20for%20maintenance%20of%20virologic%20suppression%20in%20adults%20living%20with%20human%20immunodeficiency%20virus%20type%201:%20results%20through%20week%20144%20from%20the%20phase%203,%20noninferiority%20TANGO%20randomized%20trial&amp;author=O%20Osiyemi&amp;author=S%20De%20Wit&amp;author=F%20Ajana&amp;volume=75&amp;publication_year=2022&amp;pages=975-986&amp;pmid=35079789&amp;doi=10.1093/cid/ciac036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Llibre JM, Brites C, Cheng CY, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76:720–729.
</cite> [<a href="https://doi.org/10.1093/cid/ciac130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10021070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35235656/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Efficacy%20and%20safety%20of%20switching%20to%20the%202-drug%20regimen%20dolutegravir/lamivudine%20versus%20continuing%20a%203-%20or%204-drug%20regimen%20for%20maintaining%20virologic%20suppression%20in%20adults%20living%20with%20human%20immunodeficiency%20virus%201%20(HIV-1):%20week%2048%20results%20from%20the%20phase%203,%20noninferiority%20SALSA%20randomized%20trial&amp;author=JM%20Llibre&amp;author=C%20Brites&amp;author=CY%20Cheng&amp;volume=76&amp;publication_year=2023&amp;pages=720-729&amp;pmid=35235656&amp;doi=10.1093/cid/ciac130&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Punekar YS, Parks D, Joshi M, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021;22:423–433.
</cite> [<a href="https://doi.org/10.1111/hiv.13050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8248313/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33529489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=HIV%20Med&amp;title=Effectiveness%20and%20safety%20of%20dolutegravir%20two-drug%20regimens%20in%20virologically%20suppressed%20people%20living%20with%20HIV:%20a%20systematic%20literature%20review%20and%20meta-analysis%20of%20real-world%20evidence&amp;author=YS%20Punekar&amp;author=D%20Parks&amp;author=M%20Joshi&amp;volume=22&amp;publication_year=2021&amp;pages=423-433&amp;pmid=33529489&amp;doi=10.1111/hiv.13050&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Alvarez H, Rava M, Martinez C, et al. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: a Spanish nationwide cohort. HIV Med. 2022;23:825–836.
</cite> [<a href="https://doi.org/10.1111/hiv.13265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35234328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=HIV%20Med&amp;title=Predictors%20of%20low-level%20HIV%20viraemia%20and%20virological%20failure%20in%20the%20era%20of%20integrase%20inhibitors:%20a%20Spanish%20nationwide%20cohort&amp;author=H%20Alvarez&amp;author=M%20Rava&amp;author=C%20Martinez&amp;volume=23&amp;publication_year=2022&amp;pages=825-836&amp;pmid=35234328&amp;doi=10.1111/hiv.13265&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Alvarez H, Mocroft A, Ryom L, et al. Plasma human immunodeficiency virus 1 RNA and CD4+ T-cell counts are determinants of virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND cohort study. Clin Infect Dis. 2023;77:593–605.
</cite> [<a href="https://doi.org/10.1093/cid/ciad219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10893964/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37052343/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Plasma%20human%20immunodeficiency%20virus%201%20RNA%20and%20CD4+%20T-cell%20counts%20are%20determinants%20of%20virological%20nonsuppression%20outcomes%20with%20initial%20integrase%20inhibitor-based%20regimens:%20a%20prospective%20RESPOND%20cohort%20study&amp;author=H%20Alvarez&amp;author=A%20Mocroft&amp;author=L%20Ryom&amp;volume=77&amp;publication_year=2023&amp;pages=593-605&amp;pmid=37052343&amp;doi=10.1093/cid/ciad219&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–1951.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(14)61170-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25103176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Ritonavir-boosted%20darunavir%20combined%20with%20raltegravir%20or%20tenofovir-emtricitabine%20in%20antiretroviral-naive%20adults%20infected%20with%20HIV-1:%2096%20week%20results%20from%20the%20NEAT001/ANRS143%20randomised%20non-inferiority%20trial&amp;author=F%20Raffi&amp;author=AG%20Babiker&amp;author=L%20Richert&amp;volume=384&amp;publication_year=2014&amp;pages=1942-1951&amp;pmid=25103176&amp;doi=10.1016/S0140-6736(14)61170-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Eron J, Hung CC, Baril JG, et al. Brief Report: virologic response by baseline viral load with dolutegravir plus lamivudine vs dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: Pooled analysis. J Acquir Immune Defic Syndr. 2020;84:60–65.
</cite> [<a href="https://doi.org/10.1097/QAI.0000000000002302" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31977595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;title=Brief%20Report:%20virologic%20response%20by%20baseline%20viral%20load%20with%20dolutegravir%20plus%20lamivudine%20vs%20dolutegravir%20plus%20tenofovir%20disoproxil%20fumarate/emtricitabine:%20Pooled%20analysis&amp;author=J%20Eron&amp;author=CC%20Hung&amp;author=JG%20Baril&amp;volume=84&amp;publication_year=2020&amp;pages=60-65&amp;pmid=31977595&amp;doi=10.1097/QAI.0000000000002302&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Zhao F, Rao M, Chen W, et al. Dolutegravir plus lamivudine dual-drug regimen in treatment-naive HIV-1-infected patients with high-level viral load: preliminary data from the real world. J Acquir Immune Defic Syndr. 2022;91:S16–S19.
</cite> [<a href="https://doi.org/10.1097/QAI.0000000000003053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36094510/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;title=Dolutegravir%20plus%20lamivudine%20dual-drug%20regimen%20in%20treatment-naive%20HIV-1-infected%20patients%20with%20high-level%20viral%20load:%20preliminary%20data%20from%20the%20real%20world&amp;author=F%20Zhao&amp;author=M%20Rao&amp;author=W%20Chen&amp;volume=91&amp;publication_year=2022&amp;pages=S16-S19&amp;pmid=36094510&amp;doi=10.1097/QAI.0000000000003053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Hidalgo-Tenorio C, Pasquau J, Vinuesa D, et al. DOLAVI real-life study of dolutegravir plus lamivudine in naive HIV-1 patients (48 weeks). Viruses. 2022;14:524.
</cite> [<a href="https://doi.org/10.3390/v14030524" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8951045/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35336931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Viruses&amp;title=DOLAVI%20real-life%20study%20of%20dolutegravir%20plus%20lamivudine%20in%20naive%20HIV-1%20patients%20(48%20weeks)&amp;author=C%20Hidalgo-Tenorio&amp;author=J%20Pasquau&amp;author=D%20Vinuesa&amp;volume=14&amp;publication_year=2022&amp;pages=524&amp;pmid=35336931&amp;doi=10.3390/v14030524&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Li J, Chen D, Wen Z, et al. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naive HIV-1-infected adults. Medicine (Baltimore). 2022;101:e31100.
</cite> [<a href="https://doi.org/10.1097/MD.0000000000031100" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9592519/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36281149/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine%20(Baltimore)&amp;title=Real-world%20efficacy%20and%20safety%20of%20dolutegravir%20plus%20lamivudine%20versus%20tenofovir%20plus%20lamivudine%20and%20efavirenz%20in%20ART-naive%20HIV-1-infected%20adults&amp;author=J%20Li&amp;author=D%20Chen&amp;author=Z%20Wen&amp;volume=101&amp;publication_year=2022&amp;pages=e31100&amp;pmid=36281149&amp;doi=10.1097/MD.0000000000031100&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Cabello-Ubeda A, de Quiros JCL, Martín Carbonero L, et al. 48-week effectiveness and tolerability of dolutegravir(DTG) + lamivudine (3TC) in antiretroviral-naive adults living with HIV: a multicenter real-life cohort. PLoS One. 2022;17:e0277606.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0277606" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9678299/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36409695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=48-week%20effectiveness%20and%20tolerability%20of%20dolutegravir(DTG)%20+%20lamivudine%20(3TC)%20in%20antiretroviral-naive%20adults%20living%20with%20HIV:%20a%20multicenter%20real-life%20cohort&amp;author=A%20Cabello-Ubeda&amp;author=JCL%20de%20Quiros&amp;author=L%20Mart%C3%ADn%20Carbonero&amp;volume=17&amp;publication_year=2022&amp;pages=e0277606&amp;pmid=36409695&amp;doi=10.1371/journal.pone.0277606&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>Gan L, Xie X, Fu Y, et al. Comparison of dolutegravir+lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naive patients infected with HIV: preliminary results from clinical practice. Exp Rev Anti-infect Ther. 2023;22:877–884.</cite> [<a href="https://doi.org/10.1080/14787210.2023.2279719" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37927079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Rev%20Anti-infect%20Ther&amp;title=Comparison%20of%20dolutegravir+lamivudine%20and%20bictegravir/emtricitabine/tenofovir%20alafenamide%20in%20antiretroviral%20therapy-naive%20patients%20infected%20with%20HIV:%20preliminary%20results%20from%20clinical%20practice&amp;author=L%20Gan&amp;author=X%20Xie&amp;author=Y%20Fu&amp;volume=22&amp;publication_year=2023&amp;pages=877-884&amp;pmid=37927079&amp;doi=10.1080/14787210.2023.2279719&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>Rolle CP, Berhe M, Singh T, et al. Sustained virologic suppression with dolutegravir/lamivudine in a test-and-treat setting through 48 weeks. Open Forum Infect Dis. 2023;10:ofad101.
</cite> [<a href="https://doi.org/10.1093/ofid/ofad101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10034754/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36968959/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Open%20Forum%20Infect%20Dis&amp;title=Sustained%20virologic%20suppression%20with%20dolutegravir/lamivudine%20in%20a%20test-and-treat%20setting%20through%2048%20weeks&amp;author=CP%20Rolle&amp;author=M%20Berhe&amp;author=T%20Singh&amp;volume=10&amp;publication_year=2023&amp;pages=ofad101&amp;pmid=36968959&amp;doi=10.1093/ofid/ofad101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Martinez-Sanz J, Ron R, Moreno E, et al. Similar CD4/CD8 ratio recovery after initiation of dolutegravir plus lamivudine versus dolutegravir or bictegravir-based three-drug regimens in naive adults with HIV. Front Immunol. 2022;13:873408.
</cite> [<a href="https://doi.org/10.3389/fimmu.2022.873408" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9009371/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35432298/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Similar%20CD4/CD8%20ratio%20recovery%20after%20initiation%20of%20dolutegravir%20plus%20lamivudine%20versus%20dolutegravir%20or%20bictegravir-based%20three-drug%20regimens%20in%20naive%20adults%20with%20HIV&amp;author=J%20Martinez-Sanz&amp;author=R%20Ron&amp;author=E%20Moreno&amp;volume=13&amp;publication_year=2022&amp;pages=873408&amp;pmid=35432298&amp;doi=10.3389/fimmu.2022.873408&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Acquired Immune Deficiency Syndromes (1999) are provided here courtesy of <strong>Wolters Kluwer Health</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1097/QAI.0000000000003600"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/qai-99-93.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (86.6 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11970585/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11970585/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11970585%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11970585/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11970585/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11970585/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/39806529/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11970585/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/39806529/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11970585/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11970585/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="ZJ0EoEdDGgAmOOln3dtaf8WppuOt1XqYJZCYKtpKna8H2aoCLZmn7QNOAK3p8ZTN">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
